Rare cases of autoinflammatory neutrophilic dermatoses (AINDs) have been reported in
patients during pregnancy with associated adverse maternal and fetal outcomes. Due to the …

ABSTRACT Introduction In 2022, US Food and Drug Administration (FDA) approved the first
biologics, intravenous spesolimab, for acute flare of generalized pustular psoriasis (GPP) …

Generalized pustular psoriasis (GPP) is a rare and potentially life‐threatening skin disease
and the clinical heterogeneity of which is largely unknown. Retrospective cohort analysis …

A key principle of clinical studies and case reports is that they should reflect the
demographics and epidemiology of the patient population concerned. Here, we have …

Pathologists provide valuable input in the dermatological care of pregnant patients in
various contexts. This article provides dermatopathology updates on cutaneous changes …

Generalized pustular psoriasis (GPP) is the most severe form of pustular psoriasis and
affects large areas of the body. GPP is a rare disease, and has a variable presentation; thus …

Abstract Purpose of Review The purpose of this paper is to discuss the evaluation and
management of the most encountered pustular dermatoses in the inpatient setting. Recent …

Psoriasis is a common inflammatory skin condition with an estimated prevalence of 1.5% in
the United Kingdom. Its management has evolved rapidly over the last 15 years as our …

Although the use of biologics has led to great improvement in psoriasis patients, the
treatment of psoriasis during pregnancy still faces many challenges. We herein report on a …

Generalized pustular psoriasis (GPP) in pregnancy can lead to severe complications for
both mother and fetus. The treatment of this disease is challenging, especially in recalcitrant …